Literature DB >> 35524036

Semaglutide in routine clinical practice: interesting news from real-world evidence.

G Formoso1, M G Baroni2,3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35524036     DOI： 10.1007/s40618-022-01810-w

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   5.467


× No keyword cloud information.
  7 in total

1.  2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  John B Buse; Deborah J Wexler; Apostolos Tsapas; Peter Rossing; Geltrude Mingrone; Chantal Mathieu; David A D'Alessio; Melanie J Davies
Journal:  Diabetologia       Date:  2020-02       Impact factor: 10.122

Review 2.  Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat.

Authors:  G Iacobellis; M G Baroni
Journal:  J Endocrinol Invest       Date:  2021-10-13       Impact factor: 4.256

3.  Correction to: Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.

Authors:  Chiara Di Loreto; Viviana Minarelli; Giovanni Nasini; Roberto Norgiolini; Paola Del Sindaco
Journal:  Diabetes Ther       Date:  2022-06       Impact factor: 3.595

Review 4.  Long-Acting Injectable GLP-1 Receptor Agonists for the Treatment of Adults with Type 2 Diabetes: Perspectives from Clinical Practice.

Authors:  Mario Luca Morieri; Angelo Avogaro; Gian Paolo Fadini
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-09       Impact factor: 3.249

Review 5.  GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.

Authors:  Michael A Nauck; Daniel R Quast; Jakob Wefers; Juris J Meier
Journal:  Mol Metab       Date:  2020-10-14       Impact factor: 7.422

6.  Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups.

Authors:  Jean-François Yale; Ulrik Bodholdt; Andrei-Mircea Catarig; Sergiu Catrina; Alice Clark; Neda Rajamand Ekberg; Umut Erhan; Patrick Holmes; Søren Tang Knudsen; Joanne Liutkus; Thozhukat Sathyapalan; Bernd Schultes; Gottfried Rudofsky
Journal:  BMJ Open Diabetes Res Care       Date:  2022-04

7.  Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients.

Authors:  P Marzullo; T Daffara; C Mele; M Zavattaro; A Ferrero; M Caputo; F Prodam; G Aimaretti
Journal:  J Endocrinol Invest       Date:  2022-04-16       Impact factor: 5.467
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.